Elisete I. Crocco, MD; John Verrinder Veasey, MD; Maria Fernanda Feitosa de Camargo Boin, MD; Rute Facchini Lellis, MD; Renata Oliveira Alves, MD
From Santa Casa de São Paulo Hospital and Medical School, Brazil. Drs. Crocco, Veasey, Boin, and Alves are from the Dermatology Clinic and Dr. Lellis is from the Department of Pathology.
This study was supported by TheraSkin Farmacêutica LTDA. Drs. Crocco, Veasey, Boin, Lellis, and Alves received a research grant from TheraSkin Farmacêutica LTDA for this study.
Correspondence: Elisete Crocco, MD, Avenida Macuco, 726/cj 2001, Moema, 04523-001, São Paulo-SP, Brazil (elisete@elisetecrocco.com.br).
Epidermal melasma is one of the most difficult dermatologic diseases to treat and control. Maintenance of clear, undamaged skin remains a treatment target for all dermatologists. This novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and RAL 0.05% has proven to be an effective, safe, and tolerable treatment option for patients with epidermal melasma.
